Table 3.

HPV18 seronegativity among the bivalent vaccine recipients (BVR) and quadrivalent vaccine recipients (QVR) (including only the samples with the shortest lag)

	HPV 18 seronegativity among trial participants 1–12 years post-vaccination with 3 doses
	Neutralising antibodies (PBNA)	Total binding antibodies (Luminex)	PBNA & Luminexa	Kappa, κ
All vaccine recipients	48/648 (7.41%)	78/648 (12.0%)	47/648 (7.25%)	0.72 (0.63–0.81)
Quadrivalent vaccine recipients	48/328 (14.6%)	76/328 (23.2%)	47/328 (14.3%)	0.71 (0.60–0.81)
Bivalent vaccine recipients	0/320 (0.00%)	2/320 (0.63%)	0/320 (0.00%)	-

^aHPV18 seronegative as measured both with the PBNA and the Luminex immunoassay.

Cohen’s Kappa coefficient comparing the results from the PBNA to that from the Luminex immunoassay.